CAS: 13292-22-3; 2,7-(Epoxypentadeca[1,11,13]Trienimino)Naphtho[2,1-B]Furan-8-Carboxaldehyde, 1,2-Dihydro-5,6,9,17,19,21-Hexahydroxy-23-Methoxy-2,4,12,16,18,20,22-Heptamethyl-1,11-Dioxo-, 21-Acetate

上下游产品

CAS号13292-46-1 利福平 | CAS号22912-88-5 3-[(2-pyrrolidi... | CAS号22912-87-4 Rifamycin,3-[[[... | CAS号35225-13-9 Rifampicin AF 013 | CAS号35831-76-6 nsc143485 | CAS号35676-77-8 nsc143488 | CAS号13292-54-1 2,7-(Epoxypenta... | CAS号14840-02-9 Rifamycin,3-[(h... | CAS号13292-43-8 NCI 143-447 | CAS号37281-41-7 Rifamycin AF/RP | CAS号37107-25-8 nsc143484

Rifampicin置于盐酸体系中,用 乙醚,水 用作溶剂,化学反应 96.0H,以88.9%的收率获得3甲酰利福平霉素
参考文献:利福平及其氨基类似物作为两性离子与细菌rna聚合酶结合的新模型
标题:利福平及其氨基类似物作为两性离子与细菌rna聚合酶结合的新模型
摘要:七个新苄基(3-9)和四个新苯乙基(10-13)的氨基类似物安莎-Macrolide利福平(1)用还原性胺化的优化方法来合成.溶液中3-13的结构是通过1D和2D NMR和ft-Ir方法确定的,而能量上最喜欢的氨基类似物的构象是使用pm5方法计算的.光谱和半实证研究表明,在含有下列物质的溶液中存在所有3-13个类似物的两性离子形式水痕迹.1 H-15 ñhsqc和1 H-15 ñhmbc结合1个h-1 ħcozy和1 H-13 C ^ Hmbc二维光谱方法证实明确地说的两性离子形式存在柄-Macrolides是的结果质子从o(8)-h酚基转移到3-13结构内的仲胺部分.1 H-1 H Noesy研究表明,C(3)位置的苄基和苯乙基氨基类似物引入的取代基的两个不同方向利福平而内的类似构柄-Bridges在溶液中.Ft-Ir研究分子1的去质子化,并将这些数据与3-13的数据进行比较,
Doi:10.1039/c2Ob26317C

专利信息

专利号:US-4743619-A
优先权日:1985-08-29
标 题 :Method of treating hepatitis
发明人：HUNG PAUL P
权利人:AMERICAN HOME PROD
摘要:The invention disclosed herein provides a method of treating an animal infected by hepatitis B virus comprising administering to such infected animal an amount of a rifamycin derivative selected from a group consisting of (a) 3-amino-4-deoxo-4-imino-rifamycin S, (b) 3-amino-4-deoxo-4-[(4-aminophenyl)sulfonyl]amino-rifamycin SV, (c) 4-O-(n-butylsulfonyl)-3-[(1-piperidinylimino)methyl]-rifamycin SV, (d) 4-O-(n-butylsulfonyl)-3-[(4-morpholinylimino)methyl]-rifamycin SV, (e) 3-[(dimethylhydrazono)methyl]-4-O-[(3-phenylpropyl)sulfonyl]-rifamycin SV, and (f) 4-deoxo-N,3-ethylidenimino-4-(methylsulfonyl)amino-rifamycin SV, said amount being effective to alleviate the effects of said hepatitis B virus. Also disclosed is a method of inhibiting the viral polymerase of hepatitis B virus by subjecting said polymerase to an amount of one of the rifamycin derivatives (a)-(f) above, said amount being effective to prevent the synthesis of hepatitis B virus by said viral polymerase. Compounds (b)-(f) described above are novel compounds.

专利号:US-4631290-A
优先权日:1985-08-29
标 题 :Method of treating hepatitis
发明人：HUNG PAUL P
权利人:AMERICAN HOME PROD
摘要:The invention disclosed herein provides a method of treating an animal infected by hepatitis B virus comprising administering to such infected animal an amount of a rifamycin derivative selected from a group consisting of (a) 3-amino-4-deoxo-4-imino-rifamycin S, (b) 3-amino-4-deoxo-4-[(4-aminophenyl)sulphonyl]amino-rifamycin SV, (c) 4-O-n-butylsulphonyl-3-[(1-piperidinylimino)methyl]-rifamycin SV, (d) 4-O-n-butylsulfonyl-3-[(4-morpholinylimino)methyl]-rifamycin SV, (e) 3-[(dimethylhydrazono)methyl]-4-O-[(3-phenylpropyl)sulfonyl]-rifamycin SV said amount being effective to alleviate the effects of said hepatitis B virus. Also disclosed is a method of inhibiting the viral polymerase of hepatitis B virus by subjecting said polymerase to an amount of one of the rifamycin derivatives (a)-(e) above, said amount being effective to prevent the synthesis of hepatitis B virus by said viral polymerase.

专利号:CN-115612114-A
优先权日:2021-07-14
标 题:Method and application of copolymer film and its enzymatic self-assembly synthesis